Lunsumio™ (mosunetuzumab-axgb) – New orphan drug approval
December 22, 2022 - Genentech announced the FDA approval of Lunsumio (mosunetuzumab-axgb), for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Download PDF
